Bifidobacterium Longum

If you have been taking a probiotic for months and want to know whether anything actually took, this is the test that answers that question. It counts how much Bifidobacterium longum, one of the most common friendly bacteria in the human gut, is present in your stool. Most probiotic strains pass straight through. One study following a single B. longum strain found it settled in for the long haul in only about a third of the healthy adults who took it.

This is a research-grade measurement, not a diagnosis. There are no validated cutoffs that say your number is too low, and no medical society recommends this test for routine care. What it gives you is a data point on your own gut, tracked over time, in a system that most people never look at until something goes wrong.

What the Test Actually Counts

The lab extracts DNA from your stool sample and uses PCR, a technique that copies a specific stretch of genetic code millions of times so it can be counted, to find sequences unique to B. longum. The result is an abundance figure: how much of this one species was in that sample.

Two details matter for how you read the number. First, PCR reads DNA, and DNA from dead bacteria amplifies just as well as DNA from living ones. A standard assay cannot tell you whether the bacteria it counted were alive and colonizing or dead and passing through. Researchers who need that distinction add a chemical pretreatment that blocks dead-cell DNA from amplifying; most routine panels do not.

Second, B. longum comes in two subspecies that behave very differently. Subspecies longum is the common adult colonizer, stable enough that strains picked up in infancy have been found still living in the same person six years later. Subspecies infantis specializes in digesting the complex sugars in breast milk and is largely an infant organism, common in some parts of the world and scarce in others. Standard assays aimed at the 16S rRNA gene, the usual bacterial ID tag, often cannot separate the two, because bifidobacteria share that sequence almost exactly. Telling them apart requires primers aimed at functional genes instead.

Celiac Disease, Polyps, and Bowel Inflammation

The most consistently replicated disease association for this organism is celiac disease. Children with active celiac disease carry significantly less B. longum in both stool and the duodenal lining than healthy children. Colorectal growths point the same direction: in a small surgical series of colon tissue, people with colorectal cancer carried on the order of several hundredfold less B. longum than people with diverticulitis, and adults with colorectal polyps show the same depletion against healthy controls.

Inflammatory bowel disease is the messy case, and any test report implying otherwise is overselling. That same surgical series found roughly 90-fold less in the tissue of its inflammatory bowel disease patients, but there were only four of them, and larger studies run the other way. Bifidobacterium was raised, not lowered, in actively inflamed ulcerative colitis tissue in one series, and a multi-cohort analysis of sequencing data found B. longum enriched rather than depleted in inflammatory bowel disease. The depletion that does reproduce in these patients is of the bacteria that make butyrate, the main fuel for colon cells, such as Faecalibacterium prausnitzii. So a low count is not a signal that your gut lining is inflamed.

What none of this means is that a number diagnoses any of these conditions. Healthy people span an enormous range, and the ranges overlap heavily with disease groups. The organism is a bystander that sometimes tracks damage to the gut lining, not a test that tells you what is causing it. If you have ongoing gut symptoms, the tests that answer the question are endoscopy, celiac serology, and fecal calprotectin, not a commensal bacterial count.

Mortality Risk

The largest hard-outcome evidence comes from a cohort of 1,337 solid organ transplant recipients followed 6.5 years, checked against metagenomes from 8,208 people in the general population. Higher B. longum abundance predicted lower all-cause death, and the link survived adjustment for recipient characteristics, organ type, and the number of drugs people were taking. The protective direction replicated in the general population sample.

These cohorts used shotgun metagenomic sequencing, which reads all the DNA in a sample, not the targeted stool PCR this test uses. The two methods measure the same organism but produce different numbers, so the mortality finding is context for why the species matters rather than a risk estimate you can apply to your own PCR result.

Metabolic and Liver Signals

In a study of 341 people with normal blood sugar followed for four years, the ones who went on to develop type 2 diabetes already had less B. longum at baseline than matched controls who did not, and abundance tracked inversely with fasting glucose. This is an association in a small nested case-control design, not a screening tool, but it is one of the few human datasets showing the signal appearing before the disease.

Fecal abundance also runs lower with higher visceral fat, higher body mass index, and more severe fatty liver disease. In infants born with biliary atresia, a bile duct blockage requiring surgery in the first months of life, having detectable B. longum before six months was associated with a much better chance of keeping their own liver rather than going on to a transplant.

Gut-Brain and Systemic Associations

Depletion shows up outside the gut too, though each of these rests on a single cross-sectional study with no independent replication yet. Children with migraine have lower fecal B. longum, and the lowest levels track with concurrent abdominal pain and raised fecal calprotectin, a marker of intestinal inflammation. Elderly women with sarcopenia, the age-related loss of muscle mass and strength, carry less of it than healthy peers.

The direction of cause runs both ways here and nobody has untangled it. A six-week randomized trial in people with irritable bowel syndrome gave a specific B. longum strain daily and found lower depression scores and quieter amygdala responses on brain imaging, which argues the bacteria do something rather than just marking who is sick. But supplementing a strain and measuring your own resident population are different things, and a trial showing one does not validate the other as a test.

Why a Single Reading Can Fool You

Start with the variability, because it is the biggest problem with this measurement. In one quantitative daily-sampling study, most gut bacterial genera swung more within a single person over time than they differed between people; other datasets find the reverse for most genera, so how general that pattern is remains contested. Bifidobacterium sits at the high-variability end either way. It shows day-to-day variation above 30 percent on consecutive collections, and absolute abundances can shift up to a hundredfold across six weeks. One sample is a snapshot of a moving target.

Three other things distort a reading:

• Stool consistency and transit time: looser, faster-moving stool dilutes bacterial density. A reading taken during a week of soft stools is not comparable to one taken during a normal week.
• Lab-to-lab differences: identical homogenized stool samples sent to different commercial services come back with results that differ as much as samples from different people. Collection tube, storage buffer, and DNA extraction method all bend the number.
• Which gene the assay targets: results vary depending on whether the lab amplifies a functional gene or the generic 16S tag, and assays that assume a fixed 16S copy number can compute abundances that exceed 100 percent of the sample.

Because of all this, the only version of this test worth paying for is the repeated version, using the same lab and the same collection method every time.

Tracking Your Trend

Given the noise, no single result should change anything you do. What is useful is a trajectory: your own baseline, then a repeat after you have changed something specific, then a check at least once a year. Get a baseline, retest three to six months after starting a probiotic or a serious fiber change, then annually.

Two rules make that comparison mean something. Use the same lab every time, because cross-lab numbers are not comparable. And collect under similar conditions, ideally during a stretch of normal bowel habits rather than during a bout of loose stools or right after a course of antibiotics.

One limit on the retest-to-check-your-probiotic plan: if you take a specific commercial strain, a species-level PCR cannot tell that strain apart from the B. longum already living in you. Distinguishing an administered strain from resident populations requires strain-specific primers built from comparative genomics, which research labs use and routine panels generally do not. A rise after supplementation is consistent with the strain taking hold. It does not prove it.

What to Do With an Unexpected Result

If your number comes back far lower than you expected, the first move is to repeat it before doing anything else, given how much a single sample swings. If the second reading agrees with the first, the question becomes what else is true at the same time.

Low B. longum alongside ongoing diarrhea, blood in the stool, unexplained weight loss, or a family history of inflammatory bowel disease is a reason to pursue real diagnostics rather than gut-health products. Fecal calprotectin tells you whether there is actual intestinal inflammation, and you can order it directly. Celiac antibody testing rules in or out the condition where this depletion is best documented. A gastroenterologist is the next call for endoscopy, and persistent bleeding or weight loss warrants that call regardless of what any microbiome panel says.

Low B. longum with no symptoms at all is a different situation, and a much weaker one. There is no evidence that acting on an isolated low value in a healthy person prevents anything. In healthy siblings of people with Crohn's disease, three weeks of prebiotic fiber raised bifidobacteria substantially more than it did in the diagnosed patients, but fecal calprotectin did not change significantly. The bacteria moved; the inflammation marker did not.

The more useful reading of this test is as one line in a broader picture. Paired with calprotectin, a full microbiome profile, and the rest of your metabolic panel, a persistently low count is a nudge to look harder at diet quality and fiber intake. On its own, it is a number to watch, not a number to treat.